Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare's board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited standalone and consolidated financial results on August 8, 2025. On a consolidated basis, revenue from operations grew about 28% year-on-year to Rs. 1,403.8 crore, while profit after tax jumped roughly 47% to Rs. 30.2 crore (EPS of Rs. 6.39 vs Rs. 4.62). Standalone numbers were weaker, with revenue falling about 35% to Rs. 79.4 crore and PAT declining around 67% to Rs. 7 crore. The company also extended the deadline to acquire stakes in four distribution targets (Well Wisher Pharma, Khera Medisolutions, AV Medisolutions, and Anand Medical Distributors) via an SPV from August 15, 2025 to November 30, 2025. During the quarter it acquired a 70% stake in Ramson Medical Distributors and increased its holding in Peerless Biotech to 76%. Auditor MSKA & Associates issued an unmodified (clean) review conclusion.
Strong consolidated growth driven by scaling up of acquired distribution businesses should be positive for the stock, though the sharp standalone revenue decline signals that the parent's organic business is being deliberately run down in favour of the group-level distribution model. The acquisition deadline extension is a minor delay but no deal terms have changed.